Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Oncotrace

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual...

After latest Xarelto setback, J&J, Bayer forge ahead with 5 new trials

Johnson & Johnson and Bayer are launching five new clinical trials to test their blood thinner Xarelto in people with heart disease and other coronary conditions. The companies will test Xarelto (r...

After latest Xarelto setback, J&J, Bayer forge ahead with 5 new trials

Johnson & Johnson and Bayer are launching five new clinical trials to test their blood thinner Xarelto in people with heart disease and other coronary conditions. The companies will test Xarelto (r...

Janssen responds to FDA's Xarelto CRL; resubmits sNDA

Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, German drug major Bayer's (BAYN: DE) partner for Xarelto (rivaroxaban) in the USA, last Friday submitted the Complete Response...

F.D.A. Expedites Review of New Uses for Xarelto, an Anticlotting Drug

Companies want to expand uses of drugs like Xarelto as others lose patent protection.

FDA Again Rejects Xarelto for ACS

(MedPage Today) -- The FDA delivered a second blow to the makers of rivaroxaban (Xarelto) in their bid to treat patients with acute coronary syndromes (ACS).

Bayer’s Xarelto gets EU approval for treatment of pulmonary embolism

Regulators in Europe have given the green light to Bayer‘s anticoagulant Xarelto for the treatment of pulmonary embolism and the prevention of recurrent deep vein thrombosis. Approval by the Eur...

FDA rejects Bayer-J&J's Xarelto for acute coronary syndrome

The FDA turned down for the second time an application for the expanded use of blood thinner Xarelto, or rivaroxaban, in pati -More- 

NICE yes for Xarelto to treat blood clots

NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in its final guidance that Xarelto is now an option for treating...

Price discounts on alcohol in a city in northern England.

Aims To describe the extent and nature of price discounts on alcohol in Newcastle upon Tyne, England. Methods An observational survey in stores licensed for off-sales in December 2010 to January 2011....

Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing?

OBJECTIVES: To assess the impact of competition on the consumer price and the average price paid by the National Health System (NHS) under reference pricing in the Spanish generic market. METHODS: Des...

16 for the price of 10: effects of a ban on multi-buy alcohol.

Multi-buy is one method by which retailers discount alcoholic beverage sales. It is common in the UK. A Scottish ban on multi-buys had an immediate impact on sales. Because other methods for lowering...

Group selection and inclusive fitness are not equivalent; the Price equation vs. models and statistics.

It is often suggested that any group selection model can be recast in terms of inclusive fitness. A standard reference to support that claim is "'Quantitative genetics, inclusive fitness, and group se...

Book Review Quirks of Human Anatomy Lewis I. Held Jr New York , Cambridge University Press , 2009 Hardback ISBN 978-0-51848-2 , Price $115.00 Paperback ISBN 978-0-521-73233-8 , Price $34.00 272 pp. On the Shoulders of Giants: Eponyms and Names in Obstetri